ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Tuberculosis-infected macrophage exosomal miR-125b-5p induces osteoporosis by targeting IGF2 through the PI3K/AKT pathway.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.Molecular diversity · 2026Article
- Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation.International journal of nanomedicine · 2026Review
- The mechanism of action and therapeutic potential of macrophages in osteoporosis: from polarization balance to targeted regulation.Frontiers in immunology · 2026Review
- The osteoclast blind spot and other unresolved mechanisms in the exosomal theory of tuberculosis-induced osteoporosis.Immunologic research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTuberculosis (TB) is a major infectious disease that can lead to systemic complications, including osteoporosis, particularly in immunocompromised individuals. Exosomal miRNAs derived from TB-infected macrophages have been implicated in various pathophysiological processes, including bone metabolism. This study investigates how exosomal miR-125b-5p from TB-infected macrophages contributes to osteoporosis by targeting insulin-like growth factor 2 (IGF2) and modulating the PI3K/AKT signaling pathway.
methodsWe analyzed NHANES data to compare bone mineral density in TB patients and healthy controls. In vitro experiments were conducted with Mycobacterium tuberculosis-infected peritoneal macrophages from C57BL/6 mice, isolating exosomes and using Western blot, flow cytometry, and bioinformatics tools to assess the role of miR-125b-5p in regulating osteogenic markers. In vivo studies in mouse models were performed to evaluate the impact of exosomal miR-125b-5p on bone density and structure.
resultsExosomes from TB-infected macrophages were found to contain elevated levels of miR-125b-5p, which targeted IGF2 and inhibited the PI3K/AKT pathway, leading to impaired osteoblast function and reduced bone formation. Knockdown of miR-125b-5p partially restored osteogenic markers and bone density. Furthermore, IGF2 silencing exacerbated bone loss, confirming the critical role of IGF2 in TB-induced osteoporosis.
conclusionThis study demonstrates that miR-125b-5p from TB-infected macrophages promotes osteoporosis by disrupting the IGF2/PI3K/AKT signaling axis. Targeting this pathway could provide a potential therapeutic strategy for managing TB-induced osteoporosis. Further clinical studies are necessary to validate these findings and explore additional therapeutic options.
Indexed as
Identifiers
40956311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.